Blautia faecis as Next Generation Probiotics

Blautia faecis (B. faecis) DSM33383 could be developed as a therapeutic drug, either through its supernatant, isolated bioactive compounds, or as a Live Biotherapeutic Product (LBP). Creative Biolabs has 10+ years of experience providing CRO services with a skilled team of scientists who will work with you in developing your probiotic of interest.

Introduction of B. faecis

B. faecis cells are Gram-stain-positive, strictly anaerobic, nonmotile coccobacilli that are 1.0-2.3×0.5-0.8 mm in size. After 72 h at 37℃ on GAM agar, cells are non-spore-forming, circular, umbonate, pale grey opaque colonies with intact edges. Catalase and oxidase activity tests are negative. The type of strain, M25T (=KCTC 5980T=JCM 17205T) was isolated from human faeces. The G+C content of the genomic DNA of the type of strain is 41.6 mol%. Comparative 16S rRNA gene sequencing showed that strain M25T was closely related to Ruminococcus obeum and Blautia glucerasea HFTH-1T (96.17%) within the family Lachnospiraceae. For future commercial product development, a B. faecis strain like DSM33383 should not be considered conventional probiotics.

Health Benefits of B. faecis for Respiratory Infectious Diseases

The researchers have identified the B. faecis DSM33383 strain, which decreased the TNF-induced production of IL-8 by the intestinal epithelial cell line HT-29. The beneficial effects of this strain were further studied in two preclinical models following influenza. The intragastrical administration of B. faecis DSM33383 led to protection in influenza-infected mice suffering from an Streptococcus pneumoniae (S.p) and, to a lesser extent, from a Salmonella enterica serovar Typhimurium (S.t) secondary infection. This study suggested that B. faecis DSM33383 may be a promising candidate for the prevention and management of respiratory infectious diseases.

Effect of <em>B. faecis</em> DSM33383 supplementation during IAV infection on secondary <em>Streptococcus pneumoniae</em> infection. Fig.1 Effect of B. faecis DSM33383 supplementation during IAV infection on secondary Streptococcus pneumoniae infection. (Verstraeten, 2022)

What Services Can We Provide for B. faecisat Creative Biolabs?

B. faecis Related Products at Creative Biolabs

  • Strain Products

We supply a variety of B. faecis strains of different preservation numbers. If you need other strains, please contact us.

  • Customized strain culture supernatant. (e.g.: for animal research)
  • Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)

Creative Biolabs’ scientists are highly qualified with extensive experience and exceptional skills in the fields of LBP development. Our goal is to provide our customers with affordable development services and reliable results. Please feel free to contact us for the best solution.

Reference

  1. Verstraeten, S.; et al. Description of a Newly Isolated Blautia faecis Strain and Its Benefit in Mouse Models of Post-Influenza Secondary Enteric and Pulmonary Infections. Nutrients. 2022, 14(7): 1478.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutics Drug Discovery

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Contact us

Copyright © 2022 Creative Biolabs. All Rights Reserved.

Inquiry Basket